The Global Personalized Therapy Biosimulation Market research report is a complete study that summarizes the most recent changes and advancements in the Personalized Therapy Biosimulation industry, with 2018 acting as the base year and the forecast year being 2021–2028. The analysis provides useful details on the market's size, share, sales channels, distribution system, market segmentation, consumer needs, industry trends, and potential for future growth. The research also looks at both global and regional market growth. The paper examines the COVID-19 pandemic's implications for the market for Personalized Therapy Biosimulation and its key segments.
The global personalized therapy biosimulation market size reached USD 1,061.7 Million in 2020 and is expected to register a revenue CAGR of 14.6% during the forecast period, according to the latest analysis by Emergen Research. Rising incidence of drug relapse and drug resistance cases and increasing application of quantitative system pharmacology in drug development processes are some key factors driving global personalized therapy biosimulation market revenue growth.
Drug development is a lengthy, complex, multifaceted, and costly process, with high failure rates and fewer drugs receiving U.S. Food & Drug Administration (FDA) approval. The low success rate, increasing R&D expenditure, and rising incidence of drug resistance in cancer, epilepsy, and tuberculosis, among others, are some factors driving the rising need for incorporating biosimulation techniques for the development of new generations of drugs. The majority of patients show resistance to novel targeted drugs or classical chemotherapeutic agents and do not respond to standard cancer treatment options such as chemotherapy and radiation therapy, thereby leading to a higher cancer recurrence rate. In recent years, the majority of biopharmaceutical companies have been employing modeling and simulation techniques in the drug discovery and development process, ranging from target identification and validation through the analysis of preclinical data to the analysis of phase I, II, and III clinical trial data for optimizing doses for safety and efficacy. Hence, the majority of pharmaceutical and biotechnology companies are incorporating biosimulation in clinical studies to determine a patient’s Therapy Response Index (TRI) to understand whether a patient will respond to standard care treatment, identify optimal therapies, and thereby improve clinical efficacy, avoid ineffective treatment, and improve the overall survival rate of patients. This is expected to drive the growth of the market to a significant extent going forward.
The study outlines the rapidly evolving and growing market segments along with valuable insights into each element of the industry. The industry has witnessed the entry of several new players, and the report aims to deliver insightful information about their transition and growth in the market. Mergers, acquisitions, partnerships, agreements, product launches, and joint ventures are all outlined in the report.
The leading market contenders listed in the report are:
Cellworks Group Inc., Certara USA Inc., Simulation Plus Inc., Schrodinger Inc., In Silico Biosciences Inc., Genedata AG, Physiomics plc, Insilico Biotechology AG, Chemical Computing Group ULC (CCG), and Evidera Inc
Target Audience of the Global Personalized Therapy Biosimulation Market Report:
Key Market Players
Investors
Venture capitalists
Small- and medium-sized and large enterprises
Third-party knowledge providers
Value-Added Resellers (VARs)
Global market producers, distributors, traders, and suppliers
Research organizations, consulting companies, and various alliances interested in this sector
Government bodies, independent regulatory authorities, and policymakers
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Market Segmentations of the Personalized Therapy Biosimulation Market
This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2021 and 2028. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Personalized Therapy Biosimulation market on the basis of product, application, and region:
Segments Covered in this report are:
Product Outlook (Revenue, USD Billion; 2018–2028)
Software
Services
Therapeutic Area Outlook (Revenue, USD Billion; 2018–2028)
Oncology
Others
Application Outlook (Revenue, USD Billion; 2018–2028)
Software segment is expected to account for largest revenue share over the forecast period due to increasing adoption of biosimulation software by pharmaceutical and biotechnology companies, Contract Research Organizations, regulatory agencies, and academic and research institutes to accelerate drug development process and rapid technological advancements and up-gradation in the software.
Oncology segment revenue is expected to expand at a rapid CAGR over the forecast period owing to rising prevalence of cancer, increasing adoption of personalized medicine approach for cancer treatment and increasing use of biosimulation platform to predict individual response to cancer therapeutics and minimize drug resistance among cancer patients.
Drug discovery segment revenue is expected to register a significantly robust CAGR over the forecast period owing to increasing use of biosimulation technique in drug discovery process ranging from target validation, lead identification, lead optimization, to product characterization.
Pharmaceutical & biotechnology companies segment is expected to account for largest revenue share over the forecast period owing to increasing adoption of computer modelling approach for development of safe and effective medication, streamlining clinical trial process, reducing costs involved in production of new drugs, improving selection of targeted population, and developing advanced therapeutics for cancer.
North America is expected to account largest revenue share over the forecast period due to increasing demand for biomedical simulations, increasing adoption of personalized therapy approach, increasing number of clinical trial process, and increasing implementation of computational modelling in clinical trial process.
Additional information offered by the report:
Along with a complete overview of the global Personalized Therapy Biosimulation market, the report provides detailed scrutiny of the diverse market trends observed on both regional and global levels.
The report elaborates on the global Personalized Therapy Biosimulation market size and share governed by the major geographies.
It performs a precise market growth forecast analysis, cost analysis, and a study of the micro- and macro-economic indicators.
It further presents a detailed description of the company profiles of the key market contenders.
Thank you for reading our report. Customization of the report is available according to the requirements of our clients. Kindly get in touch with us to know more about the customization options, and our team will ensure the report is tailored according to your needs.
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
